Research programs working toward an HIV cure. Covers reservoir reduction, prevention policy, tumor-like tissue models, and vaccine development.
Researchers have developed a new strategy to determine the early stages of HIV infection, allowing for targeted treatment and study. The approach uses a modified enzyme immunoassay test to distinguish between recent and long-term infections, enabling more precise diagnosis and monitoring of disease spread.
A study by Johns Hopkins Bloomberg School of Public Health found that educational interventions can cut high-risk sexual behaviors in half and more than double the regular use of condoms. The study enrolled 3,706 men and women from public health clinics and showed significant reductions in high-risk behaviors over a one-year period.
Despite initial evidence of HIV-1 infection, researchers found no conclusive cases of transient infection among exposed infants. The study suggests laboratory contamination or mislabeling as the cause of false positive test results.
William E. Paul, a prominent NIH AIDS researcher, has been awarded the 1998 Abbott Laboratories Award in Clinical and Diagnostic Immunology. He made significant contributions to understanding cytokine biology, T-cell reproduction, and B-cell activation.
A recent study found that risk factors for HIV infection among married women in India include having a sex partner with a sexually transmitted disease. The researchers discovered a significant correlation between HIV transmission and the cultural norm of not discussing sexual behavior, emphasizing the need for accessible STD prevention...
A study published in the Journal of the American Medical Association found that certain symptoms like fever, joint pain, and night sweats can identify people with recent HIV infection before a positive blood test. The researchers screened over 3,800 patients and found that those with these symptoms were more likely to have the virus.
The FDA has approved the first phase of a new AIDS vaccine developed at St. Jude Children's Research Hospital, which aims to trigger immune responses to multiple HIV isolates using envelope proteins. The vaccine combines 23 different envelopes representing various HIV strains and is expected to last one to two years.
The study aims to measure how effectively combination drug therapy works during the early stages of HIV infection, with a focus on reducing damage caused by the virus. Researchers hope to determine the optimal duration of treatment for maximum benefit and assess the impact of early treatment on immune system chemicals.
Researchers have found that cidofovir, a new antiviral drug, can slow the progression of cytomegalovirus (CMV) retinitis, a common cause of vision loss and blindness in AIDS patients. The study showed that both low and high doses of the drug were effective, allowing for less frequent treatment compared to traditional options.
A recent NIH study found that a combination of a protease inhibitor and two nucleoside analogue reverse transcriptase inhibitors can significantly reduce the occurrence of AIDS-defining illnesses or death. The study, ACTG 320, demonstrated improved survival and delayed disease progression in patients receiving triple combination therapy.
Researchers found a three-drug combination of indinavir, zidovudine, and lamivudine significantly reduces AIDS symptoms and prolongs patient survival compared to two-drug combinations. The study enrolled 1,156 participants and showed a 45% reduction in disease progression events.
Researchers have identified key chemokine receptors that enable HIV to infect immune system cells, including CCR5 and CCR-3. Understanding these interactions could lead to the development of new treatments and prevention strategies for HIV/AIDS.